Bausch + Lomb
New Hydrophobic, Acrylic IOL Combines Predictable Astigmatism Correction with Superior Rotational Stability
MILAN, ITALY — Bausch + Lomb, the global eye health company, announced the launch of its new enVista® TORIC, its first hydrophobic acrylic intraocular lens (IOL) for astigmatism correction, at the 2012 Congress of European Society of Cataract and Refractive Surgeons (ESCRS) in Milan, Italy.
Bausch + Lomb’s enVista TORIC lens represents a significant step forward in IOL technology, providing predictable astigmatism correction through its unique haptic design. The lens features unique single-piece, modified-C haptic design that delivers superior rotational stability compared to other IOLs.The haptics are step-vaulted designed to secure a predictable astigmatism correction and minimize posterior capsular opacification (PCO), a common long-term problem with IOLs that can cause patient vision to become clouded post-surgery. The unique combination of aspheric, aberration-free Advanced Optics technology with a glistening-free hydrophobic acrylic material helps the enVista TORIC lens deliver a new standard in patient outcomes.
“The rotational stability of a toric IOL is critical to providing the best possible outcome for a patient. If the lens rotates a patient’s vision will become suboptimal,” said Luis Cadarso, Clinica Cadarso, Pontevedra, Spain. “In my experience, the new enVista TORIC is very stable. Since this lens is also clinically proven to be glistening-free, it allows me to provide better, more consistent vision for my astigmatic patients.”
“The new enVista TORIC lens is the latest innovation from Bausch + Lomb designed to meet the needs of both customers and patients. It extends the unique benefits of the enVista lens launched at ESCRS last year. The enVista lens is manufactured using a glistening-free, foldable hydrophobic acrylic IOL material developed by Advanced Vision Science, a Santen subsidiary. Together, our unique Advanced Optics technology, clinically proven glistening-free material, and superior rotational stability, deliver optimal outcomes to patients” said Cal Roberts M.D., executive vice president and chief medical officer, Bausch + Lomb. “The addition of this new lens to our portfolio means that Bausch + Lomb now offers surgeons a more complete range of IOLs to meet their patients’ needs.”
The enVista TORIC lens has two key features that enhance its rotational stability: unique fenestrated, step-vaulted haptics and a 56 degree contact angle compared to a contact angle of 45 degrees with the leading competitor to provide added stability. Trials have shown that 91% of patients have less than or equal to five degrees rotation from operative day to the six month visit compared to 81% of patients fitted with the market leader’s IOL.In fact the absolute mean rotation at six month visit was 3 degrees. In addition, there was mean decentration of 0.28mm compared to a mean decentration of 0.5mm with competitor IOLs. The lens is easily implantable through a 2.2-mm incision.
Glistenings are fluid-filled microvacuoles that can form within an IOL and are common in some hydrophobic acrylic IOLs. Some studies indicate that glistenings may not only present an aesthetic issue post-surgery for surgeons, but can impact patients’ visual function, including visual acuity and contrast sensitivity. No glistenings were detected with the enVista lens at any time during a 2-year prospective study of 172 eyes.
Bausch + Lomb will be hosting an educational symposium, “Seeing is believing: Optimising outcomes for cataract surgery and astigmatism management“ on September 10, 2012 from 13:00-14:00 in Brown 3 Room, South Wing Level +2 at Milano Congressi. The event features presentations by enVista TORIC and enVista trialists: Dr Edoardo Ligabue, Ophthalmic Center, San Siro Clinic in Milan, Italy, Dr Jean-Luc Febbraro. Fondation Ophtalmologique Adolphe de Rothschild – Service du Dr. Gatinel in Paris, France, Professor Manfred Tetz, Augen-Tagesklinik Spreebogen Berlin in Germany and Dr Luis Cadarso, Clinica Cadarso, Pontevedra in Spain.
The enVista TORIC lens received CE Mark approval in the European Union in April 2012 and is not approved for sale in the US.
About Bausch + Lomb
Bausch + Lomb is one of the best-known and most respected healthcare companies in the world. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. Founded in 1853, the company is headquartered in Rochester, N.Y., and employs more than 10,000 people worldwide. Its products are available in more than 100 countries. More information is available at www.bausch.com.
News Media Contacts:
Bausch + Lomb
+44 20 8781 5709 or +44 7713 340657
Bausch + Lomb
+1 (949) 521-7948
BioComm Network, Inc.on Behalf of Bausch + Lomb
+1 (949) 494-3140